Novo Nordisk A/S (NYSE:NVO) Shares Bought by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 7.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,079 shares of the company’s stock after purchasing an additional 1,303 shares during the period. Congress Wealth Management LLC DE’s holdings in Novo Nordisk A/S were worth $1,555,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the 3rd quarter valued at $28,000. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Dunhill Financial LLC grew its holdings in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after acquiring an additional 311 shares during the period. Albion Financial Group UT raised its position in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $46,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $70.18 on Friday. The firm has a market capitalization of $314.93 billion, a P/E ratio of 21.33, a PEG ratio of 0.90 and a beta of 0.42. The stock has a fifty day moving average of $82.52 and a 200-day moving average of $99.54. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $69.77 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 21st. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.